Related Experiment Videos
Absence of a prothrombotic state in restenotic patients?
M J Brack1, R S More, S Pringle
1Academic Department of Cardiology, Glenfield Hospital, Leicester, UK.
Insights
This study found no reliable blood markers to predict restenosis after percutaneous transluminal coronary angioplasty (PTCA). Higher platelet counts were observed in restenotic patients, but activation markers did not differ, suggesting current tests cannot identify those at risk.
Area of Science:
- Cardiology
- Thrombosis
- Interventional Cardiology
Background:
- Restenosis is a significant complication following percutaneous transluminal coronary angioplasty (PTCA).
- Identifying patients predisposed to restenosis is crucial for optimizing treatment strategies.
Purpose of the Study:
- To investigate whether prothrombotic markers in blood can predict restenosis after PTCA.
- To assess coagulation, fibrinolytic, and platelet activation markers in patients undergoing PTCA.
Main Methods:
- Blood samples were collected from patients undergoing PTCA for stable angina.
- Assays were performed for coagulation factors, fibrinolytic factors (including tissue-type plasminogen activator [t-PA]), and platelet activation markers.
- Patients were monitored for restenosis, defined as >50% loss in luminal diameter gain.
Main Results:
- Restenosis occurred in 35% of patients post-PTCA.
- No significant differences were found in coagulation, fibrinolytic, or platelet activation markers between restenotic and non-restenotic groups.
- A significantly higher platelet count was observed in patients who developed restenosis.
Conclusions:
- Pre-existing imbalances in prothrombotic/antithrombotic status do not appear to predict restenosis after PTCA.
- Despite higher platelet counts in restenotic patients, markers of platelet activation were similar, limiting predictive value.
- Simple blood tests assessing thrombotic state before PTCA are unlikely to identify patients at risk for restenosis.
Aims:
To determine whether, in patients undergoing percutaneous transluminal coronary angioplasty (PTCA), there are prothrombotic markers indicating those with a predisposition to restenosis.
Methods:
Venous blood samples were obtained from patients undergoing PTCA for chronic stable angina. Patients with restenotic lesions, conduit stenoses or occlusive lesions were not included in the study. Samples were assayed for coagulation factors (fibrinopeptide A, antithrombin III, protein C), fibrinolytic factors [tissue-type plasminogen activator (t-PA), alpha 2 antiplasmin, plasminogen activator inhibitor (PAI-1)] and markers of platelet activation (platelet factor 4, beta thromboglobulin).
Results:
Of 46 patients who underwent successful PTCA, restenosis, defined as loss in absolute gain of more than 50%, occurred in 16 (35%). The minimal luminal diameter (mean +/- SD) at follow-up in those who had suffered restenosis was 1.07 +/- 0.7 mm compared with 1.73 +/- 0.5 mm in the non-restenotic patients. However, no significant differences in the levels of markers of platelet activation, coagulation factors, or fibrinolytic factors were observed between the two groups. The only significant difference between the groups was a higher platelet count in the restenotic patients [median (interquartile range): 263 (247-278) versus 224 (175-263), P < 0.05].
Conclusion:
Our results suggest that patients who suffer restenosis following PTCA appear to have no clearly detectable pre-existing imbalance in their prothrombotic/antithrombotic status. Although the platelet count was higher in restenotic patients, the levels of markers of platelet activation were no different in the two groups. Thus, it is at present unlikely that simple blood assays before PTCA assessing an individual's 'thrombotic state' can help to predict which of the 30-40% of patients undergoing PTCA will suffer restenosis.